$ Value
$0
Shares
6,638
Price
$0
Filed
Feb 20
Insider
Name
Thakkar Roopal
Title
EVP, R&D and CSO
CIK
0002004979
Roles
Transaction Details
Transaction Date
2026-02-18
Code
A
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
60,413
Footnotes
Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. | Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,313 on February 18, 2027, 7,312 on February 18, 2028, and 7,312 on February 18, 2029.
Filing Info
Thakkar Roopal's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-27 | ABBV | F | $1.9M |
| 2026-02-18 | ABBV | A | $0 |
| 2026-02-18 | ABBV | A | $0 |
| 2026-02-18 | ABBV | A | $0 |
| 2026-02-18 | ABBV | A | $0 |
| 2026-02-18 | ABBV | A | $0 |
Other Insiders at ABBV (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| RAPP EDWARD J | — | — | 2026-03-31 |
| Alpern Robert J | — | — | 2026-03-31 |
|
SALEKI-GERHARDT AZITA
EVP, CHIEF OPERATIONS OFFICER
|
— | — | 2026-02-27 |
|
Michael Robert A.
CHAIRMAN OF THE BOARD AND CEO
|
— | — | 2026-02-27 |
|
Michael Robert A.
CHIEF EXECUTIVE OFFICER
|
— | — | 2026-02-18 |
|
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
|
— | — | 2026-02-27 |
|
Donoghoe Nicholas
EVP, CHIEF BUS/STRAT OFFICER
|
— | — | 2026-02-27 |
|
Reents Scott T
EVP, CHIEF FINANCIAL OFFICER
|
— | — | 2026-02-27 |
|
Siatis Perry C
EVP, GC AND SECRETARY
|
— | $9.5M | 2026-03-02 |
| Quaggin Susan E | — | — | 2026-03-31 |
|
Thakkar Roopal
EVP, R&D and CSO
|
— | — | 2026-02-27 |
|
Purdue David Ryan
SVP, Controller
|
— | $1.2M | 2026-03-04 |
|
Crum Demetris D
EVP, CHIEF HR OFFICER
|
— | — | 2026-02-27 |